Jing Shan¹, Catherine King^2,3, Harunor Rashid^3,4, Veysel Kayser^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070851 - 30 December 2025

Abstract Objectives: B-cell maturation antigen (BCMA)-targeted antibody–drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This study aimed to synthesize the available evidence on the safety and efficacy of BCMA-ADCs in development for RRMM. Methods: A systematic search was conducted using six bibliographic databases and ClinicalTrials.gov up to November 2024. Studies were eligible if they were human clinical trials or animal studies evaluating BCMA-ADCs and reported efficacy and safety outcomes. Data extraction and quality assessments were conducted using validated tools, including ROBINS-I… More >

Neha Raina¹, Radha Rani², Mahika Kanojia², Avril Mathias³, Keshav Raj Paudel^4,*, Ashish Garg⁵, Hardeep Singh Tuli⁶, A. T. M. Mijanur Rahman⁷, Vetriselvan Subramaniyan⁸, Madhu Gupta^2,*

Oncology Research, Vol.33, No.10, pp. 2787-2831, 2025, DOI:10.32604/or.2025.066624 - 26 September 2025

Abstract Breast cancer is among the most prevalent cancers in females globally and has the highest mortality rate. The emergence of pharmacologic resistance in breast cancer is a significant challenge for researchers in the pursuit of effective treatment. Investigations in cancer nanotechnology have been transformed by the advancement of smart polymers, lipids, and inorganic materials. Research is now being conducted in the field of innovative nano-pharmaceutical formulations aimed at enhancing the efficacy and durability of chemotherapy. Nanotechnology-based delivery systems are beneficial for combating breast cancer due to theranostic applications, augmented drug encapsulation, decreased degradation, and minimal… More >

Rosa Scarpitta^1,#, Emiliano Cappello^1,#, Alice Cangialosi¹, Veronica Gori¹, Giulia De Luca^1,2, Giovanni Gori³, Guido Bocci^1,*

Oncology Research, Vol.33, No.10, pp. 2603-2656, 2025, DOI:10.32604/or.2025.066260 - 26 September 2025

Abstract Central nervous system (CNS) tumors are the most common solid tumors in pediatric patients and the leading cause of childhood cancer-related mortality. Their rarity compared to adult cancers has made enrolling sufficient cases for clinical trials challenging. Consequently, pediatric CNS tumors were long treated with adult protocols despite distinct biological and clinical characteristics. This review examines key aspects of phase I pediatric oncology trials, including study design, primary outcomes, and pharmacological approaches, along with secondary considerations like clinical responses and ethical aspects. Firstly, we evaluated all phase I trial protocols focusing on pediatric CNS tumors… More > Graphic Abstract

Yuriy Mayasin¹, Maria Osinnikova¹, Daria Osadchaya¹, Victoria Dmitrienko¹, Anna Gorodilova¹, Chulpan Kharisova¹, Kristina Kitaeva¹, Ivan Filin¹, Valeria Solovyeva¹, Albert Rizvanov^1,2,*

Oncology Research, Vol.33, No.9, pp. 2221-2242, 2025, DOI:10.32604/or.2025.064677 - 28 August 2025

Abstract Melanoma is a malignant neoplasm with a high propensity to metastasize, arising from melanocytes and contributing significantly to global morbidity and mortality. Despite the demonstrated efficacy of many immunotherapy approaches, these methods rely on direct destruction of tumor cells with minimal impact on the aggregate of nearby non-tumor cells, the extracellular matrix, and blood vessels that form the tumor microenvironment (TME). The TME is known to be heterogeneous and dynamic, exerting both antitumor and pro-tumor effects depending on the specific features and stage of carcinogenesis. TME has been shown in several studies to promote… More >

LUCIANA SABOYA^1,2, KEINI BUOSI¹, TIAGO SILVA², ELAINE CANDIDO¹, JOSIANE MORARI³, LICIO A. VELLOSO³, SHAHROKH F. SHARIAT^4,5,6,7, MARCUS V. SADI², LEONARDO O. REIS^1,8,9,*

Oncology Research, Vol.33, No.6, pp. 1495-1503, 2025, DOI:10.32604/or.2025.061812 - 29 May 2025

Abstract Objective: To determine the safety and the role of modulating cytokines and proteases in the immune response to intravesical Bacillus Calmette-Guérin (BCG) when primed with systemic intradermal BCG. Methods: Phase 1 and mechanistic longitudinal, prospective, single-blind randomized study (NCT04806178). Twenty-one non-muscle invasive urothelial bladder cancer patients undergoing intravesical adjuvant BCG after transurethral resection of bladder tumor (TURBT) in a teaching hospital between September 2021 and April 2023 were randomized to 0.1 mL of intradermal BCG vaccine or placebo (0.9% saline) administered 15 days before the start of intravesical BCG therapy. Blood samples were evaluated mechanistically… More >

Ayda Baghery Saghchy Khorasani¹, Mahda Delshad², Mohammad-Javad Sanaei^2,3, Atieh Pourbagheri-Sigaroodi², Ali Pirsalehi⁴, Davood Bashash^2,*

BIOCELL, Vol.49, No.4, pp. 539-562, 2025, DOI:10.32604/biocell.2025.059970 - 30 April 2025

Abstract Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third leading cause of cancer-related mortality globally. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is critically involved in HCC pathogenesis, stimulating uncontrolled cell proliferation, survival, and tumor progression. The overactivation of this pathway is strongly linked to poor prognosis, making it a crucial target for therapeutic intervention. The oncogenic roles of PI3K/AKT/mTOR components in HCC have been highlighted, noting that class I PI3K deregulation, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) upregulation, and mTOR overexpression could be associated… More >

TATIANA KURILO^*, REBECCA D. PENTZ

Oncology Research, Vol.32, No.9, pp. 1401-1406, 2024, DOI:10.32604/or.2024.050266 - 23 August 2024

Abstract Objectives: Rural patients have poor cancer outcomes and clinical trial (CT) enrollment compared to urban patients due to attitudinal, awareness, and healthcare access differential. Knowledge of cancer survival disparities and CT enrollment is important for designing interventions and innovative approaches to address the stated barriers. The study explores the potential disparities in cancer survival rates and clinical trial enrollments in rural and urban breast and lung cancer patients. Our hypotheses are that for both cancer types, urban cancer patients will have longer 5-year survival rates and higher enrollment rates in clinical trials than those in… More >

Alexis E. Te¹, Christina Sze¹, Steven A. Kaplan², Bilal Chughtai¹

Canadian Journal of Urology, Vol.30, No.1, pp. 11408-11413, 2023

Abstract Introduction: A common indication for benign prostate hyperplasia (BPH) therapies is failure to improve with medical therapy. However, pivotal Federal Drug Administration (FDA) registered randomized clinical trials (RCTs) for minimally invasive surgical therapies (MISTs) are designed to be compared to either sham or placebo while off medical therapy at baseline, and as an alternative to medical therapy. There are few if any RCTs reporting the MISTS efficacy in patients with true medical therapy failure. We report on the efficacy of robotic water jet ablation therapy (RWT) and TURP in patients who have failed to improve with… More >

Kussil Oumedjbeur¹, Nicholas J. Corsi², David Bouhadana³, Ahmed Ibrahim⁴, David-Dan Nguyen⁵, Imad Matta⁴, Adel Arezki³, Iman Sadri³, Tawfik Elsherbini⁶, Naeem Bhojani⁴, Dean S. Elterman⁵, Bilal Chughtai⁷, Brian T. Helfand⁸, Alexander P. Glaser⁸, Vincent Misrai⁹, Steven Kaplan¹⁰, Peter Gilling¹¹, Neil Barber¹², Mihir Desai¹³, Gopal H. Badlani¹⁴, Alexis E. Te⁷, Claus G. Roehrborn¹⁵, Kevin C. Zorn⁴

Canadian Journal of Urology, Vol.30, No.5, pp. 11650-11658, 2023

Abstract Introduction: To report the 5-year efficacy and safety of Aquablation compared with transurethral resection of the prostate for the management of lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with prostate volumes 50-80 mL.
Materials and methods: In a large double-blinded, multicenter, and prospective randomized controlled trial, 96 randomized men with 50-80 mL prostates who underwent Aquablation or transurethral prostate resection were prospectively identified for subgroup analysis. Follow up was performed for up to 5 years. The primary efficacy endpoint was the reduction in International Prostate Symptom Score (IPSS) at 6 months. The primary… More >

POOJA BHADORIYA¹, RICHA SHARMA¹, REKHA MEHROTRA¹, SIMRAN KAUR¹, ISHA SRIVASTAVA¹, MUKUL JAIN², PRASHANT KAUSHIK^3,*

BIOCELL, Vol.47, No.9, pp. 1915-1930, 2023, DOI:10.32604/biocell.2023.029564 - 28 September 2023

Abstract In the present medicine world antibiotic resistance is one of the key threats to universal health coverage. Researchers continue to work hard to combat this global health concern. Phage therapy, an age-old practice during the early twentieth century, was outshined by the discovery of antibiotics. With the advent of widespread antibiotic resistance, phage therapy has again redeemed itself as a potential alternative owing to its adeptness to target bacteria precisely. Limited side effects, the ability to migrate to different body organs, a distinct mode of action, and proliferation at the infection site, make phages a… More > Graphic Abstract